文献速递临床免疫分子诊断质量管理与危急值

BD Veritor SARS-CoV-2 即时检测临床性能评估:与 PCR 及 Sofia 2 抗原检测的比较

Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test.
PubMed 文献 · J Clin Microbiol · 2020-12-17

两项研究评估 BD Veritor 检测 SARS-CoV-2 核衣壳抗原的临床性能:研究1比较 Veritor 与 Lyra PCR(251例有症状成人),研究2比较 Veritor 与 Sofia 2 抗原检测(361例有症状成人)。Veritor 与 Sofia 2 一致性高,但与 PCR 相比阳性符合率未达100%。

要点

  • Veritor 与 Sofia 2 抗原检测高度一致,PPA 97.4%、NPA 98.1%、OPA 98.1%。
  • 与 Lyra PCR 相比,Veritor 的 PPA 在 0-1 和 0-6 DSO 范围为 81.8-87.5%。
  • Veritor 满足 FDA EUA 抗原检测标准(0-5 DSO PPA 83.9%,0-6 DSO PPA 82.4%)。

核心结论

  • Veritor 与 Sofia 2 对 SARS-CoV-2 检测高度一致,但相较 PCR 阳性符合率不足100%。

研究设计与样本

  • 研究1:251例有症状成人(≤7天症状出现,≥18岁),比较鼻拭子 Veritor 与鼻咽/口咽 Lyra PCR。
  • 研究2:361例有症状成人(≤5天症状出现,≥18岁),比较鼻拭子 Veritor 与 Sofia 2 抗原检测。

主要发现

  • 研究1中,Veritor 对比 Lyra 的 PPA 在 0-1 和 0-6 DSO 范围为 81.8-87.5%。
  • 研究2中,Veritor 对比 Sofia 2 的 PPA、NPA、OPA 分别为 97.4%、98.1%、98.1%。
  • 不一致分析:1例 Lyra 阳性被 Veritor 漏检,5例 Lyra 阳性被 Sofia 2 漏检;1例 Veritor 阳性而 Lyra 阴性。

关键数值与推荐

  • Veritor 满足 FDA EUA 抗原检测标准:0-5 DSO PPA 83.9%,0-6 DSO PPA 82.4%。

临床怎么用

  • Veritor 可使用易于采集的鼻拭子进行更快速的 COVID-19 检测。
  • Veritor 与 PCR 相比阳性符合率不足100%,阴性结果需结合临床判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 nucleocapsid antigen (Veritor), a chromatographic immunoassay used for SARS-CoV-2 point-of-care testing, was evaluated using nasal specimens from individuals with COVID-19 symptoms. Two studies were completed to determine clinical performance. In the first study, nasal specimens and either nasopharyngeal or oropharyngeal specimens from 251 participants with COVID-19 symptoms (≤7 days from symptom onset [DSO], ≥18 years of age) were utilized to compare Veritor with the Lyra SARS-CoV-2 PCR assay (Lyra). In the second study, nasal specimens from 361 participants with COVID-19 symptoms (≤5 DSO, ≥18 years of age) were utilized to compare performance of Veritor to that of the Sofia 2 SARS Antigen FIA test (Sofia 2). The positive, negative, and overall percent agreement (PPA, NPA, and OPA, respectively) were the primary outcomes. In study 1, the PPA for Veritor, compared to Lyra, ranged from 81.8 to 87.5% across the 0 to 1 and 0 to 6 DSO ranges. In study 2, Veritor had PPA, NPA, and OPA values of 97.4, 98.1, and 98.1%, respectively, with Sofia 2. Discordant analysis showed one Lyra positive missed by Veritor and five Lyra positives missed by Sofia 2; one Veritor positive result was negative by Lyra. Veritor met FDA emergency use authorization (EUA) acceptance criteria for SARS-CoV-2 antigen testing for the 0 to 5 and 0 to 6 DSO ranges (PPA values of 83.9% and 82.4%, respectively). Veritor and Sofia 2 showed a high degree of agreement for SARS-CoV-2 detection. The Veritor test allows for more rapid COVID-19 testing utilizing easy-to-collect nasal swabs but demonstrated <100% PPA compared to PCR.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Young S, Taylor SN, Cammarata CL, et al. Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. J Clin Microbiol. 2020. PMID: 33023911. doi:10.1128/JCM.02338-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。